<DOC>
	<DOCNO>NCT01253278</DOCNO>
	<brief_summary>The study drug LY2393910 evaluate possible treatment diabetes . The primary purpose patient 's participation study help answer follow research question ( ) , provide treatment diabetes : - The safety LY2393910 side effect might associate follow 2 week dose - How long take body absorb remove LY2393910 follow dose 2 week - How daily dose LY2393910 affect blood level sugar ( glucose ) , insulin naturally occur substance body - How daily dose LY2393910 affect cell produce insulin - Any difference LY2393910 take daily dos morning evening</brief_summary>
	<brief_title>A Multiple-Ascending Dose Study Type 2 Diabetes Mellitus Patients</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Diagnosis type 2 diabetes mellitus Must stable treatment regimen ( maintain diet/exercise therapy without metformin ) least 4 week prior study entry Have glycated haemoglobin ( HbA1c ) value great equal 6.5 % less equal 10.0 % stable treatment regimen Weigh 45.0 kg Have Body Mass Index ( BMI ) great equal 18.5 less equal 40.0 kg/m2 Are willing able conduct selfblood glucose monitoring test Are currently enrol , discontinue within last 30 day clinical trial involve use investigational drug device study drug use study , concurrently enrol type medical research judge compatible study Use insulin diabetic control 6 consecutive day within 1 year prior study entry Use thiazolidinediones within 3 month , oral antidiabetic ( OADs ) , apart metformin , within 1 month prior study entry . Metformin acceptable study Previous myocardial infarction , stroke transient ischaemic event ( 'TIA ' ) , clinically significant coronary event symptom within 6 month prior study entry Subjects evidence heart insufficiency , hypokalaemia , family history longQTsyndrome receive drug extend QT interval Clinically significant peripheral vascular disease Clinical evidence active diabetic proliferative retinopathy Known significant autonomic neuropathy Any patient experience ketoacidotic episode require hospitalisation last 6 month Symptomatic hyperglycemia exhibit significant osmotic symptom ( polyuria polydipsia ) , unanticipated weight loss dehydration Evidence hepatitis B and/or positive hepatitis B surface antigen , screen Subjects average weekly alcohol intake exceed 21 unit per week ( male ) 14 unit per week ( female ) Subjects heavy smoker ( &gt; 10 cigarette , equivalent , per day ) unable unwilling refrain nicotine CRU admission Exclusion Criteria EU Site Regular use know drug abuse and/or positive finding urinary drug screen Evidence human immunodeficiency virus ( HIV ) and/or positive HIV antibody Evidence hepatitis C and/or positive hepatitis C antibody</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>